Update your treatment options with this breast cancer thought-leader discussion, with associated slide deck and eNewsflash, featuring valuable updates and expert perspectives on exciting new developments in the management of breast cancer released at the 2017 Oncology Annual Meeting in Chicago.
Jun 9, 2017
Jun 9, 2018
Abstract #1000: MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy
Abstract #1001: Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18)
Abstract #1002: A phase II trial of the CDK4/6 inhibitor palbociclib (P) as single agent or in combination with the same endocrine therapy (ET) received prior to disease progression, in patients (pts) with hormone receptor positive (HR+) HER2 negative (HER2-) metastatic breast cancer (mBC) (TREnd trial)
Abstract #1010: Everolimus (EVE) plus endocrine therapy in patients with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (BC): First- and second-line data from the BOLERO-4 study
Abstract #1018: Predicting sensitivity to palbociclib with early circulating tumor DNA dynamics in the PALOMA-3 trial
Abstract #1019: Abemaciclib for the treatment of brain metastases (BM) secondary to hormone receptor positive (HR+), HER2 negative breast cancer
Abstract #1020: Health-related quality of life (HRQoL) of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with ribociclib + letrozole: Results from MONALEESA-2
Abstract #1038: Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC)
Abstract #1047: First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 safety results
Abstract #1050: Predictors of prolonged benefit from palbociclib (PAL) plus fulvestrant (F) in women with endocrine-resistant hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) advanced breast cancer (ABC) in PALOMA-3
Robert Coleman, MD, FRCP, FRCPEMedical Director, prIME Oncology
University of Sheffield
Weston Park Hospital
Sheffield, United Kingdom
Angelo Di Leo, MD, PhDIstituto Toscano Tumori, Hospital of Prato
Joyce O’Shaughnessy, MDBaylor University Medical Center
Dallas, Texas, United States
After successful completion of this educational activity, participants should be able to:
- Examine the role of cyclins and cyclin-dependent kinases in the biology of ER-positive disease and the mechanism of action of the range of CDK4/6 inhibitors in development
- Summarize the clinical application of novel combinations of targeted and endocrine therapy for the first- and second-line treatment of ER-positive, HER2-negative advanced breast cancer
- Select appropriate treatment combinations for ER-positive, HER2-negative breast cancer, and identify the optimal sequence of treatment options
This educational activity is supported by a grant from Novartis Oncology.
Enduring Materials From a Certified Activity
This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by prIME Oncology for a certified live event, this activity does not offer continuing education credit.
This activity is provided by prIME Oncology.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.